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Anemia is a complication of chronic kidney disease. It
is seen early in the course of chronic kidney disease,
with the decline in hemoglobin concentration starting
at levels of creatinine clearance of around 70 mL/min
in men and 50 mL/min in women, and becomes more
severe as renal failure progresses [1]. Anemia is
predictive of morbidity and mortality from car-
diovascular causes in patients with chronic kidney
disease or on dialysis [2]. It leads to reduced oxygen
delivery to tissues, causing organ dysfunction. It also
causes hemodynamic adaptations including a high
cardiac output state to maintain adequate tissue
oxygenation leading to left ventricular dilatation and
hypertrophy [3].
Traditionally, the target hematocrit level for therapy
is 30–33%, though there is little supporting data. Prior
to the mid-1980s, repeated blood transfusion was the
only strategy for managing the severe anemia that
complicates chronic kidney disease. Early inves-
tigations have established the erythropoietic effects
of androgens, but the effect was too weak and un-
predictable to be adopted as a routine therapy. The
mechanism of action is not completely understood. It
was initially considered to be due to an increase in
erythropoietin production. However, it was subse-
quently observed that androgen did not elicit an in-
crease in serum erythropoietin levels in all subjects.
Other possible mechanisms include synergistic action
with erythropoietin, an increase in the sensitivity of
erythroid progenitors to erythropoietin, increased red
blood cell survival, or a direct effect on erythropoietic
precursor cells at various stages of maturity.
In the mid-1980s, recombinant human erythropoietin
(rHuEPO) was developed and was proven to be effective
in treating renal-related anemia. Recombinant HuEPO
acts by binding to the dimerized erythropoietin receptor
on the surface of erythroid progenitor cells, leading to
phosphorylation of tyrosine residues on several
intracellular molecules, gene activation in the cell
nucleus, and stimulating proliferation and inhibiting
apoptosis of the erythroid progenitor cells [4]. Due to its
relatively short half-life (8.5 hours), rHuEPO is usually
given once to thrice per week.
Later on, darbepoetin alfa (Aranesp™; Amgen Inc.,
Thousand Oaks, CA, USA) was developed [5]. It is a
hyperglycosylated analog of rHuEPO that stimulates
erythropoiesis by the same mechanism as the
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endogenous hormone. Darbepoetin has five N-linked
glycosylation (carbohydrate) side chains, whereas both
rHuEPO and the endogenous hormone have three [5].
This leads to darbepoetin having a three-fold terminal
half-life (25.3 hours) and greater in vivo biologic
activity compared to conventional rHuEPO. Less
frequent dosing is needed, with expected increase in
compliance and improvement in the treatment of renal
anemia. A number of studies have shown the efficacy
and safety of using darbepoetin in patients with chronic
kidney disease or on dialysis [6,7]. It has also been
shown to be efficacious when administered once every
month in patients with chronic kidney disease [6].
However, the optimal dosing interval of darbepoetin in
patients on dialysis remains unknown.
In this issue of the Hong Kong Journal of
Nephrology, Tang et al describe a study using once
monthly darbepoetin in peritoneal dialysis patients
previously on rHuEPO [8]. Fourteen patients were
recruited, 11 of whom completed the study. There was
a mean drop in hemoglobin level from a baseline of
1.03 g/dL, which was statistically insignificant (95%
CI: –2.23, 0.27). The authors concluded that
darbepoetin administered once a month effectively
maintained hemoglobin level in continuous ambulatory
peritoneal dialysis patients. Although the sample size
was small and there was an insignificant drop in
hemoglobin, this study provides prove-of-principle
evidence that monthly rHuEPO treatment is practically
feasible.
Apart from erythropoietin, there are other novel
agents being developed for correction of anemia related
to kidney disease without the need for frequent
injection. One of the new advances is continuous
erythropoietin receptor activator (CERA) [9]. CERA
was created by integration of a single 30 kDa polymer
chain into the erythropoietin molecule, doubling its
molecular weight and prolonging its elimination half-
life to about 130 hours. CERA has a lower affinity for
the erythropoietin receptor compared with epoetin in
vitro. However, it interacts and leads to continuous
activation of the erythropoietin receptor through its half-
life. With the prolonged elimination half-life, CERA
has increased erythropoietic activity in vivo [10].
Preliminary data from phase III clinical studies suggests
that administration of CERA once every 3–4 weeks is
safe and effective [9].
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Also in the developmental stages are the
erythropoietin-mimetic peptides. These synthetic
peptide-based erythropoiesis-stimulating agents have
amino acid sequences that are completely unrelated to
that of native or recombinant erythropoietin [11].
However, they interact with and activate the eryth-
ropoietin receptor, and stimulate erythropoiesis by
the same intracellular tyrosine phosphorylation
signaling cascade. Hematide™ (Affymax Inc., Palo
Alto, CA, USA) is one of the product candidates that is
currently undergoing phase II clinical trials. As a
pegylated peptide, Hematide™ has the advantage of a
long circulating half-life and a long duration of
erythropoietic action that allows for once monthly
dosing [12]. Due to its novel amino acid sequence, it is
supposed to have a lack of cross-reactivity with anti-
erythropoietin antibodies. It could potentially be used
as rescue therapy for patients with anti-erythropoietin-
antibody-mediated pure red cell aplasia.
The first oral therapy for the treatment of anemia
in chronic kidney disease is in phase II of clinical
development. This oral agent is a hypoxia-inducible
factor (HIF) stabilizer. HIF is a gene product that
activates erythropoietin production during hypoxic
conditions. The HIF stabilizer inhibits the enzyme that
degrades HIF (prolyl hydroxylase) and, consequent-
ly, HIF-1 alfa is stabilized and activates erythropoie-
tin gene production. It is a novel form of therapy
to activate and regulate endogenous erythropoietin
production.
There  a re  cur ren t ly  some cont rovers ies
surrounding the use of erythropoietin and optimal
hemoglobin level in patients with renal insufficiency.
The Correction of Hemoglobin and Outcomes in Renal
Insufficiency (CHOIR) trial found that correction of
hemoglobin level to 13.5 g/dL, compared with 11.3
g/dL, was associated with increased risk and no
incremental improvement in the quality of life [13].
The Cardiovascular Risk Reduction by Early Anemia
Treatment with Epoetin Beta (CREATE) trial also
concluded that early complete correction of anemia
does not reduce the risk of cardiovascular events [14].
Thus, it is suggested that hemoglobin level might have
a J-shaped relationship with outcomes in subjects with
chronic kidney disease. On the one hand, anemia
is predictive of complications and death from
cardiovascular causes in patients with chronic kidney
disease [2]. Observational studies also indicate that
correction of anemia is associated with improved
outcomes [2,15]. On the other hand, normalization of
hemoglobin level in prospective trials involving
patients receiving hemodialysis did not lead to
improvement in left ventricular indexes or decrease
the risk of death [16].
In summary, the study by Tang et al [8] provides
evidence that monthly injection of darbepoetin alfa is
a feasible option for the treatment of anemia in
peritoneal dialysis patients. Other new agents that can
serve the same purpose without the need for frequent
injection are in the pipeline. Let’s keep our eyes and
minds open.
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